Like other sectors of the economy, the pharmaceutical industry is also feeling the effects of the significantly higher energy prices and higher costs for primary products.
(Photo: Bayer AG)
Berlin, Brussels, Frankfurt It is the largest pharmaceutical reform in 20 years and is intended to lay the foundation for a “European Health Union”. The EU Commission wants to combat the drug shortage in Europe, set incentives for innovation and initiate the development of new antibiotics. This emerges from a final draft that is available to the Handelsblatt and is to be presented on Wednesday.
The package was originally announced for mid-March, but had to be postponed due to difficult negotiations with the member states. For example, the federal government intervened in a letter to Brussels, warning of “significant risks” for the European location. The letter is available to the Handelsblatt. Numerous pharmaceutical associations also expressed concerns.
The core of the reform consists of two legislative packages, one on pharmaceutical regulation and one on patent protection. The latter affects not only the pharmaceutical industry, but also other sectors.
Read on now
Get access to this and every other article in the
Web and in our app free of charge for 4 weeks.
Further
Read on now
Get access to this and every other article in the
web and in our app.
Further